Experimental Topical Drug Shows Promise for AD, Psoriasis

In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.
MDedge News

source https://www.medscape.com/s/viewarticle/experimental-topical-drug-shows-promise-atopic-dermatitis-2024a100008l?src=rss